Primary Perspective

Diabetes | Erectile Dysfunction | Hypogonadism | Migraine | Urinary Incontinence

Home

Your certificate for continuing education credit (if applicable) will be issued from the following information.

Fields marked with an asterisk (*) are required.

Prefix:

Prefix (other):

*First Name: MI: *Last Name: *Degree(s):

Degree (add'l):

Title: *Specialty:

Specialty (other):

*Affiliation: *Practice Type:

Type (other):

Department: Years in Practice: x

Address:

Business Personal

Address Name:

*Address 1: Address 2: *City: *State:

*ZIP: *E-mail: *Day Phone: Ext.: Cell: Fax: x

What is the best time to contact you?

Because you have attended or shown interest in our programs, we may send you information on this and similar programs utilizing the e-mail address provided. You may unsubscribe at any time by clicking on the “unsubscribe” link on any e-mails sent from us.

Please do not send me information via e-mail.

We value the confidentiality of the information you choose to share with us and are committed to its protection. All personal information you provide is stored in a secure location and will never be sold or distributed to any third party.

EVALUATION

To enable us to maintain the highest scientific and educational standards when planning future activities, we would
appreciate your evaluation of this activity and its content.

PRESENTATIONS AND INTERACTIVE DISCUSSION	Excellent			Poor
	5	4	3	2	1
Insights Into Basic Science of Chronic Migraine Andrew C. Charles, MD
Overall presentation
Clinical relevance
Presentation style/visuals
Wizardry or Science of Chronic Migraine Treatment Stephen D. Silberstein, MD, FACP
Overall presentation
Clinical relevance
Presentation style/visuals
Future Directions in Treating Chronic Migraine David W. Dodick, MD, FRCP (C), FACP
Overall presentation
Clinical relevance
Presentation style/visuals
Clinical Consult: Q&A and Interactive Discussion David W. Dodick, MD, FRCP (C), FACP, and Faculty
Overall presentation
Clinical relevance
Presentation style/visuals
Activity:	Agree			Disagree
	5	4	3	2	1
As a result of this activity, I am better able to: Describe the biology, classification, and progression of chronic migraine
Explain prevailing theories about the pathophysiology of chronic migraine and review the mechanisms of action of current and future therapies
Examine current clinical trials, management strategies, and novel therapeutic modalities for improved treatment of chronic migraine
Define chronic migraine patient populations for whom prophylactic, localized therapy has shown clinical benefit and utilize prophylaxis in this population as needed
This activity:
Met my expectations
Was relevant to my clinical practice
Was presented without commercial bias
Logistics were well organized
Environment was conducive to learning
After participating in this activity, I will change my clinical practice by:

Additional comments:

POSTTEST

Please select the best answers to the posttest questions below.
1. The primary endpoint examined in the PREEMPT-1 study was the change from baseline in frequency of which of the following?
	Headache episodes
	Headache days
	Moderate to severe headache days
	Migraine days
2. When comparing the US and EU topiramate clinical trials, which two parameters had significant results for both trials?
	Acute medication use and headache days
	Migraine days and subject satisfaction
	Disability measure and responder rate (50%)
	Migraine/migrainous days and subject satisfaction
3. Which of the following is the least robust endpoint for chronic migraine trials?
	Headache episodes
	Headache days
	Migraine days
	Subject satisfaction
4. Which of the following CDH syndromes is exclusively unilateral?
	New daily persistent headache
	Chronic tension-type headache
	Chronic migraine
	Hemicrania continua
5. The proposed revisions endorsed and added to the ICHD-2R guidelines included all of the following except:
	≥15 headaches per month
	≥8 days of migraine per month for ≥3 months
	≥5 previous migraine attacks
	≥8 days of migraine per month for ≥6 months
6. Prophylactic medications that have proven efficacy for treating chronic migraine include:
	OnabotulinumtoxinA/topiramate
	Topiramate/gabapentin
	Gabapentin/divalproex
	Divalproex/propranolol
7. Accumulation of iron in the brain of patients with migraine has been shown to occur in which structure?
	Midbrain
	Occipital cortex
	Insular cortex
	Trigeminal nucleus caudalis
8. Compared with control subjects, migraine patients had increased gray matter density in which area of the brain?
	Periacqueductal gray matter
	Prefrontal cortex
	Cingulate cortex
	Bilateral insula
9. According to growing evidence that overuse of analgesic medication leads to the worsening of migraine, which of the following is correct?
	Opioid use <10 days per month is not associated with CDH
	Triptans are more likely to induce CDH than are other acute medications
	Butalbital use <10 days per month on average is associated with CDH
	Nonsteroidal use is protective in those with >15 headache days per month